<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="antiviral1\PMC3184032\results\search\drugs\results.xml">
  <result pre="protein or the enzyme neuraminidase. Combination therapy with Interferon-α and" exact="ribavirin" post="remains the backbone treatment for chronic hepatitis C; the"/>
  <result pre="Some antiviral drugs possess multiple potential clinical applications, such as" exact="ribavirin" post="for the treatment of chronic hepatitis C and respiratory"/>
  <result pre="treatment of chronic hepatitis C and respiratory syncytial virus and" exact="cidofovir" post="for the treatment of cytomegalovirus and other DNA viruses."/>
  <result pre="discussed in these sections possess other potential applications, such as" exact="ribavirin" post="for the treatment of respiratory syncytial virus (RSV) and"/>
  <result pre="ribavirin for the treatment of respiratory syncytial virus (RSV) and" exact="cidofovir" post="for the treatment of cytomegalovirus (CMV) and other DNA"/>
  <result pre="of acyclovir may still be beneficial in immunocompromised patients. Short-course" exact="prednisone" post="may be added as an adjunct to acyclovir treatment"/>
  <result pre="during the early period after transplant in patients not receiving" exact="ganciclovir" post="or valganciclovir prophylaxis.14 Acyclovir is generally well tolerated. However,"/>
  <result pre="early period after transplant in patients not receiving ganciclovir or" exact="valganciclovir" post="prophylaxis.14 Acyclovir is generally well tolerated. However, IV acyclovir"/>
  <result pre="available as an IV formulation, and an oral prodrug of" exact="cidofovir" post="(known as CMX-001) is under clinical development.28 This investigational"/>
  <result pre="is under clinical development.28 This investigational lipid ester formulation of" exact="cidofovir" post="has enhanced bioavailability, resulting in improved 50% inhibitory concentrations.28"/>
  <result pre="resulting in improved 50% inhibitory concentrations.28 Direct intraocular injection of" exact="cidofovir" post="is contraindicated due to ocular hypotony.27 Serum cidofovir concentrations"/>
  <result pre="injection of cidofovir is contraindicated due to ocular hypotony.27 Serum" exact="cidofovir" post="concentrations decline rapidly after IV infusion, with a half-life"/>
  <result pre="hours. Cidofovir is eliminated by glomerular filtration and tubular secretion;" exact="probenecid" post="reduces its excretion by blocking tubular secretion.29,30 Cidofovir is"/>
  <result pre="thereby halting viral DNA synthesis.27 The major clinical indication for" exact="cidofovir" post="is the treatment of CMV retinitis in HIV-infected patients"/>
  <result pre="CMV disease resistant or unresponsive to ganciclovir.32 Because activation of" exact="cidofovir" post="does not rely on viral kinases, it retains activity"/>
  <result pre="UL97 mutation and HSV with the TK mutation.33 Resistance to" exact="cidofovir" post="occurs when the virus develops mutations in the DNA"/>
  <result pre="Famciclovir Famciclovir is a diacetyl 6-deoxy analogue of penciclovir. Oral" exact="famciclovir" post="is rapidly absorbed and achieves a bioavailability of 77%.51"/>
  <result pre="of 77%.51 Famciclovir is metabolized into penciclovir, reaching peak plasma" exact="penciclovir" post="concentrations within 1 hour. Because of extensive hepatic metabolism,"/>
  <result pre="within 1 hour. Because of extensive hepatic metabolism, virtually no" exact="famciclovir" post="is detectable in plasma.51 Famciclovir is excreted renally as"/>
  <result pre="famciclovir is detectable in plasma.51 Famciclovir is excreted renally as" exact="penciclovir" post="and its 6-deoxy precursor.9 Famciclovir is active against HSV-1,"/>
  <result pre="extent, against EBV. Its mechanism of action is through penciclovir;" exact="penciclovir" post="triphosphate inhibits herpes DNA synthesis by acting as a"/>
  <result pre="substrate for viral DNA polymerase. The major clinical indications for" exact="famciclovir" post="use are treatment of herpes zoster, recurrent genital herpes,52"/>
  <result pre="varicella in HIV-infected patients. The most common adverse effects of" exact="famciclovir" post="are headache and nausea.54 Rare adverse events include jaundice,"/>
  <result pre="of standard CMV therapies, or whose virus is resistant to" exact="ganciclovir" post="and foscarnet.55-57 The main adverse effect of fomivirsen is"/>
  <result pre="CMV diseases in immunocompromised patients, especially those unable to tolerate" exact="ganciclovir" post="and those infected with ganciclovir-resistant virus.60,61 Foscarnet is also"/>
  <result pre="CMV.65 It is available in oral and parenteral formulations. Oral" exact="ganciclovir" post="is poorly absorbed, with a bioavailability of only 5%.65"/>
  <result pre="5%.65 Management of active CMV disease is therefore with IV" exact="ganciclovir" post="or its oral valyl prodrug valganciclovir. Intravitreal ganciclovir implants"/>
  <result pre="with IV ganciclovir or its oral valyl prodrug valganciclovir. Intravitreal" exact="ganciclovir" post="implants are also available, with minimal systemic absorption. Ganciclovir"/>
  <result pre="herpes simplex keratitis, and CMV prophylaxis in transplant recipients. Intravenous" exact="ganciclovir" post="may also be used to treat other forms of"/>
  <result pre="disease, such as colitis or esophagitis. Induction therapy with IV" exact="ganciclovir" post="for CMV retinitis in patients with AIDS has an"/>
  <result pre="95% in stabilizing disease.68 Because it is poorly absorbed, oral" exact="ganciclovir" post="should not be used for induction treatment of CMV"/>
  <result pre="or progresses in patients with advanced AIDS, oral or IV" exact="ganciclovir" post="(or valganciclovir) is given as maintenance therapy until immune"/>
  <result pre="given as maintenance therapy until immune reconstitution is achieved.69 Intravitreal" exact="ganciclovir" post="may also be surgically implanted for the treatment of"/>
  <result pre="treatment should be used together with systemic therapy with IV" exact="ganciclovir" post="or oral valganciclovir therapy. Oral ganciclovir may be used"/>
  <result pre="used together with systemic therapy with IV ganciclovir or oral" exact="valganciclovir" post="therapy. Oral ganciclovir may be used to prevent CMV"/>
  <result pre="systemic therapy with IV ganciclovir or oral valganciclovir therapy. Oral" exact="ganciclovir" post="may be used to prevent CMV in patients with"/>
  <result pre="era of highly active antiretroviral therapy. Although IV and oral" exact="ganciclovir" post="have also been used to prevent CMV disease in"/>
  <result pre="also been used to prevent CMV disease in transplant recipients," exact="valganciclovir" post="is currently the preferred drug for this indication.60,61,70 Intravenous"/>
  <result pre="valganciclovir is currently the preferred drug for this indication.60,61,70 Intravenous" exact="ganciclovir" post="is also used as a first-line treatment of CMV"/>
  <result pre="creatinine and liver enzymes. Neurotoxicity may occur occasionally. Resistance to" exact="ganciclovir" post="occurs most commonly in severely immunocompromised patients with prolonged"/>
  <result pre="prolonged exposure to the drug. The most common mechanism for" exact="ganciclovir" post="resistance is UL97 gene mutation71; this mutation leads to"/>
  <result pre="viral kinase that is necessary for the initial phosphorylation of" exact="ganciclovir" post="into its active form. A less common mechanism is"/>
  <result pre="available as topical therapy for mucocutaneous herpes. For systemic use," exact="penciclovir" post="has been reformulated into the oral prodrug famciclovir. The"/>
  <result pre="reformulated into the oral prodrug famciclovir. The antiviral activity of" exact="penciclovir" post="is similar to that of acyclovir, with efficacy against"/>
  <result pre="for prevention of CMV disease in kidney transplant recipients.78 Although" exact="ganciclovir" post="is the backbone for CMV prevention in transplant recipients,"/>
  <result pre="Valganciclovir Valganciclovir is the L-valyl ester prodrug of ganciclovir. Oral" exact="valganciclovir" post="is well absorbed and converted to ganciclovir by first-pass"/>
  <result pre="of ganciclovir. Oral valganciclovir is well absorbed and converted to" exact="ganciclovir" post="by first-pass intestinal or hepatic metabolism.79 The bioavailability of"/>
  <result pre="ganciclovir by first-pass intestinal or hepatic metabolism.79 The bioavailability of" exact="ganciclovir" post="after valganciclovir administration is about 60%, and peak plasma"/>
  <result pre="first-pass intestinal or hepatic metabolism.79 The bioavailability of ganciclovir after" exact="valganciclovir" post="administration is about 60%, and peak plasma concentrations are"/>
  <result pre="CMV retinitis in patients with AIDS.83 For immediate sight-threatening lesions," exact="valganciclovir" post="is used in combination with an intravitreal ganciclovir implant."/>
  <result pre="sight-threatening lesions, valganciclovir is used in combination with an intravitreal" exact="ganciclovir" post="implant. Valganciclovir is also used for preventing CMV disease"/>
  <result pre="of kidney, heart, or kidney-pancreas transplants.61,84 In the United States," exact="valganciclovir" post="is not approved for preventing CMV disease in liver"/>
  <result pre="higher incidence of tissue-invasive CMV disease in patients who received" exact="valganciclovir" post="vs oral ganciclovir prophylaxis. In other countries, valganciclovir is"/>
  <result pre="tissue-invasive CMV disease in patients who received valganciclovir vs oral" exact="ganciclovir" post="prophylaxis. In other countries, valganciclovir is used for preventing"/>
  <result pre="who received valganciclovir vs oral ganciclovir prophylaxis. In other countries," exact="valganciclovir" post="is used for preventing CMV disease in all solid"/>
  <result pre="Valganciclovir was recently demonstrated to be as effective as IV" exact="ganciclovir" post="for treating mild to moderate CMV disease in transplant"/>
  <result pre="as diarrhea, nausea, and vomiting, may be observed. Resistance to" exact="valganciclovir" post="occurs through mechanisms identical to those underlying ganciclovir resistance,"/>
  <result pre="Resistance to valganciclovir occurs through mechanisms identical to those underlying" exact="ganciclovir" post="resistance, ie, through mutations in the UL97 gene, which"/>
  <result pre="keratitis and acute keratoconjunctivitis.90 Once phosphorylated into its active form," exact="vidarabine" post="inhibits viral DNA polymerase. Adverse effects of ophthalmic vidarabine"/>
  <result pre="form, vidarabine inhibits viral DNA polymerase. Adverse effects of ophthalmic" exact="vidarabine" post="include irritation, pain, photophobia, lacrimation, and occlusion of the"/>
  <result pre="in elderly patients and those taking neuroaffective drugs. Emergence of" exact="amantadine" post="resistance has limited its use in the clinical setting.94,95"/>
  <result pre="2 to 4 days of treatment. Because of widespread resistance," exact="amantadine" post="is no longer recommended for empiric treatment of influenza.94,95"/>
  <result pre="is excreted in the urine. The mechanism of action of" exact="rimantadine" post="is similar to that of amantadine; it inhibits the"/>
  <result pre="currently limited by drug resistance.96,97 A few trials that compared" exact="amantadine" post="and rimantadine suggested similar efficacy; however, neurologic adverse events"/>
  <result pre="by drug resistance.96,97 A few trials that compared amantadine and" exact="rimantadine" post="suggested similar efficacy; however, neurologic adverse events are less"/>
  <result pre="rimantadine. Neuraminidase Inhibitors Oseltamivir. Oseltamivir phosphate is a prodrug of" exact="oseltamivir" post="carboxylate, which is an inhibitor of neuraminidase that is"/>
  <result pre="in the replication of influenza A and B viruses.98 Oral" exact="oseltamivir" post="is well absorbed and reaches peak serum concentrations in"/>
  <result pre="and reaches peak serum concentrations in 1 hour. Bioavailability of" exact="oseltamivir" post="phosphate is at least 75%. The prodrug oseltamivir phosphate"/>
  <result pre="Bioavailability of oseltamivir phosphate is at least 75%. The prodrug" exact="oseltamivir" post="phosphate undergoes extensive hepatic metabolism via ester hydrolysis. More"/>
  <result pre="hepatic metabolism via ester hydrolysis. More than 99% of active" exact="oseltamivir" post="carboxylate is excreted renally. Oseltamivir carboxylate, the active drug"/>
  <result pre="influenza A and B, including pandemic strains. For this indication," exact="oseltamivir" post="should be started within 48 hours of exposure and"/>
  <result pre="outbreak. A systematic review reported no statistically significant difference between" exact="oseltamivir" post="and zanamivir prophylaxis for preventing symptomatic influenza among immunocompetent"/>
  <result pre="systematic review reported no statistically significant difference between oseltamivir and" exact="zanamivir" post="prophylaxis for preventing symptomatic influenza among immunocompetent adults.100 The"/>
  <result pre="influenza among immunocompetent adults.100 The most common adverse effects of" exact="oseltamivir" post="are nausea, vomiting, diarrhea, abdominal pain, insomnia, and vertigo."/>
  <result pre="the neuraminidase gene, such as R292K101 and H274Y,98 account for" exact="oseltamivir" post="resistance. Surveillance conducted during the 2009 H1N1 influenza pandemic"/>
  <result pre="is not available orally since it is poorly absorbed.106 Inhaled" exact="zanamivir" post="produces high concentrations in the respiratory tract where influenza"/>
  <result pre="influenza virus infection occurs. About 4% to 20% of inhaled" exact="zanamivir" post="is absorbed systemically, producing peak serum concentrations at 1"/>
  <result pre="is excreted in the feces.106 The mechanism of action of" exact="zanamivir" post="is similar to oseltamivir, by inhibiting neuraminidase, which is"/>
  <result pre="of newly formed viral particles from infected cells.106 For treatment," exact="zanamivir" post="is given by inhalation twice daily for 5 days,"/>
  <result pre="given IV to treat critically ill patients with influenza.107,108 Inhaled" exact="zanamivir" post="is well tolerated.106 Acute bronchospasm with decline in respiratory"/>
  <result pre="SC IFN-α.114 Likewise, SC peginterferon-α may be more effective than" exact="lamivudine" post="in hepatitis B e antigen (HBeAg)–positive and HBeAg-negative patients"/>
  <result pre="(HBeAg)–positive and HBeAg-negative patients with CHB,115-117 and the addition of" exact="lamivudine" post="to peginterferon-α did not significantly enhance efficacy.118 Interferon-α is"/>
  <result pre="patients with CHC.124-126 However, combination therapy with IFN-α and oral" exact="ribavirin" post="is more effective than either drug used alone.127 Combining"/>
  <result pre="is more effective than either drug used alone.127 Combining oral" exact="ribavirin" post="with peginterferon-α may be more effective than combining it"/>
  <result pre="of Liver Diseases130 recommends once-weekly SC peginterferon-α combined with oral" exact="ribavirin" post="as the first line of treatment of CHC. The"/>
  <result pre="rate of intolerance to a combination regimen of IFN-α and" exact="ribavirin" post="is higher and the rate of sustained virologic response"/>
  <result pre="plus ribavirin.132 A lower SVR rate to combination peginterferon-α plus" exact="ribavirin" post="therapy was observed in patients coinfected with HCV genotype"/>
  <result pre="In general, the guidelines recommend combination therapy with peginterferon-α and" exact="ribavirin" post="for 48 weeks. Interferons are generally not recommended in"/>
  <result pre="guanine, is available in oral, aerosolized, and IV formulations. Oral" exact="ribavirin" post="is absorbed extensively, but its bioavailability is only 65%"/>
  <result pre="bioavailability is only 65% because of first-pass metabolism. Peak plasma" exact="ribavirin" post="concentrations occur within 1 to 2 hours after oral"/>
  <result pre="times higher after 4 weeks of treatment. Administration of aerosolized" exact="ribavirin" post="leads to high concentrations in the respiratory tract, with"/>
  <result pre="leads to high concentrations in the respiratory tract, with some" exact="ribavirin" post="absorbed systemically. Ribavirin is mainly excreted in the urine.149"/>
  <result pre="mainly excreted in the urine.149 The mechanism of action of" exact="ribavirin" post="is known to be diverse but is not completely"/>
  <result pre="its antiviral activity is reversed by guanosine. Its triphosphorylated form," exact="ribavirin" post="triphosphate, is a potent competitive inhibitor of inosine monophosphate"/>
  <result pre="triphosphorylated form, ribavirin triphosphate, is a potent competitive inhibitor of" exact="inosine" post="monophosphate dehydrogenase, influenza virus RNA polymerase, and mRNA guanylyltransferase."/>
  <result pre="in vitro activity and its activity against human infections. Oral" exact="ribavirin" post="is approved for use, in combination with IFN-α or"/>
  <result pre="transplant recipients. When used for the treatment of RSV pneumonia," exact="ribavirin" post="is usually given by the aerosol route, which delivers"/>
  <result pre="which delivers high concentrations at the site of infection.152 Oral" exact="ribavirin" post="has also been used with good outcomes.153 Ribavirin has"/>
  <result pre="hemorrhagic fever,160,161 Bolivian hemorrhagic fever,162 and hantavirus pulmonary syndrome.163 Aerosolized" exact="ribavirin" post="can cause sudden deterioration of respiratory function and cardiovascular"/>
  <result pre="deterioration of respiratory function and cardiovascular effects. Precipitation of inhaled" exact="ribavirin" post="may occur in ventilatory tubings. Hemolytic anemia occurs commonly,154"/>
  <result pre="may occur in ventilatory tubings. Hemolytic anemia occurs commonly,154 and" exact="ribavirin" post="should not be given to patients with preexisting medical"/>
  <result pre="suicidal ideation, and relapse of drug abuse may occur, and" exact="ribavirin" post="is contraindicated in patients with a history of, or"/>
  <result pre="acidosis. Adefovir. Adefovir dipivoxil is an acyclic nucleotide analogue of" exact="adenosine" post="monophosphate.164 Oral adefovir dipivoxil is rapidly absorbed and converted"/>
  <result pre="such as lamivudine.165 However, concomitant use with the related drug" exact="tenofovir" post="disoproxil fumarate is not recommended because of the augmented"/>
  <result pre="cytidine. Although not currently approved for the treatment of CHB," exact="emtricitabine" post="has been used clinically in combination with tenofovir in"/>
  <result pre="of CHB, emtricitabine has been used clinically in combination with" exact="tenofovir" post="in HIV/HBV–coinfected patients. Emtricitabine is very similar to lamivudine,"/>
  <result pre="because of high rates of resistance development.170 The rate of" exact="emtricitabine" post="resistance among patients with HBV monoinfection is 18% at"/>
  <result pre="of patients with CHB, including those resistant to lamivudine.172 Oral" exact="entecavir" post="is extensively absorbed: peak plasma concentrations occur in 30"/>
  <result pre="and oral bioavailability is almost 100%. Despite low plasma concentrations," exact="entecavir" post="maintains its potency by the long intracellular half-life of"/>
  <result pre="potency by the long intracellular half-life of its active metabolite" exact="entecavir" post="triphosphate. Entecavir is mainly excreted by glomerular filtration and"/>
  <result pre="filtration and active tubular secretion. The mechanism of action of" exact="entecavir" post="is somewhat unique because it inhibits 3 specific functions"/>
  <result pre="liver disease.173 In randomized trials of HBeAg-positive and HBeAg-negative patients," exact="entecavir" post="demonstrated better outcomes than lamivudine, with improvement in histologic"/>
  <result pre="and normalization or improvement of ALT levels. Adverse effects of" exact="entecavir" post="are generally mild and include headache, fatigue, nausea, diarrhea,"/>
  <result pre="rtT184S/A/I/L, rtS202G/C, or rtM250L. Among nucleoside-naive patients, the rate of" exact="entecavir" post="resistance is less than 1% after 5 years, but"/>
  <result pre="but patients with preexisting rtM204V/I have a higher rate of" exact="entecavir" post="resistance (51%) after 5 years.173 Lamivudine. Lamivudine is a"/>
  <result pre="years.173 Lamivudine. Lamivudine is a nucleoside analogue of cytosine. Oral" exact="lamivudine" post="provides bioavailability of about 85%, and peak serum concentrations"/>
  <result pre="kidneys.174 Lamivudine is phosphorylated intracellularly into its active 5′-triphosphate metabolite," exact="lamivudine" post="triphosphate. When the active metabolite is incorporated into viral"/>
  <result pre="In a double-blind study involving about 350 patients with CHB," exact="lamivudine" post="was associated with substantial histologic improvement, HBeAg antibody seroconversion,"/>
  <result pre="are common once treatment is discontinued.178 The adverse effects of" exact="lamivudine" post="are mild and include abdominal pain, nausea, and headache."/>
  <result pre="include abdominal pain, nausea, and headache. The clinical utility of" exact="lamivudine" post="is limited by the rapid development of antiviral resistance."/>
  <result pre="which occurs easily and confers cross-resistance. After 4 years of" exact="lamivudine" post="monotherapy, rtM204V/I resistance develops in up to 70% and"/>
  <result pre="is a synthetic thymidine nucleoside analogue. Unlike other anti-HBV drugs," exact="telbivudine" post="has no activity against HIV. Oral telbivudine is well"/>
  <result pre="other anti-HBV drugs, telbivudine has no activity against HIV. Oral" exact="telbivudine" post="is well absorbed and achieves peak plasma concentrations after"/>
  <result pre="inhibits HBV by competitive inhibition of viral DNA polymerase. Oral" exact="telbivudine" post="is approved for the treatment of CHB in patients"/>
  <result pre="liver inflammation and fibrosis.180,181 It is considered more effective than" exact="lamivudine" post="and adefovir.182,183 Compared with lamivudine, telbivudine was associated with"/>
  <result pre="considered more effective than lamivudine and adefovir.182,183 Compared with lamivudine," exact="telbivudine" post="was associated with a higher degree of reduction in"/>
  <result pre="or anti-HBe seroconversion. The most common adverse effects reported for" exact="telbivudine" post="are dizziness, fatigue, gastrointestinal symptoms, and rash. Unique adverse"/>
  <result pre="neuropathy or myopathy is diagnosed. The rate of resistance to" exact="telbivudine" post="is 25% after 96 weeks of treatment. Tenofovir. Tenofovir"/>
  <result pre="Tenofovir disoproxil fumarate, an acyclic nucleoside phosphonate diester analogue of" exact="adenosine" post="monophosphate, is considered one of the most potent anti-HBV"/>
  <result pre="taken with a high-fat meal. The terminal elimination half-life of" exact="tenofovir" post="is 12 to 18 hours, and it is excreted"/>
  <result pre="for conversion to tenofovir. Subsequent phosphorylation by cellular enzymes forms" exact="tenofovir" post="diphosphate, which competes with the natural substrate deoxyadenosine 5′-triphosphate"/>
  <result pre="for the treatment of CHB. In a randomized trial comparing" exact="tenofovir" post="and adefovir, a higher percentage of patients receiving tenofovir"/>
  <result pre="comparing tenofovir and adefovir, a higher percentage of patients receiving" exact="tenofovir" post="achieved HBV DNA level suppression. In HBeAg-positive patients, the"/>
  <result pre="were similar for adefovir and tenofovir.185-188 The adverse effects of" exact="tenofovir" post="include gastrointestinal symptoms, dizziness, fatigue, and headache. Renal toxicities,"/>
  <result pre="syndrome), and renal failure, have been associated with tenofovir.189-193 Primary" exact="tenofovir" post="resistance mutations have not been well defined. Although viruses"/>
  <result pre="than do wild-type viruses. One study reported rtA194T as a" exact="tenofovir" post="resistance mutation; however, this pattern was not confirmed in"/>
  <result pre="current standard treatment of CHC is peginterferon-α in combination with" exact="ribavirin" post="for 24 weeks (for HCV genotype 2 or 3)"/>
  <result pre="after completion of treatment. A combination regimen of peginterferon-α and" exact="ribavirin" post="results in SVR rates between 38% and 46%, and"/>
  <result pre="serine protease inhibitors to the backbone therapies of peginterferon-α and" exact="ribavirin" post="will emerge as the standard of care for the"/>
  <result pre="(SPRINT-2 [serine protease inhibitor therapy 2] trial), the addition of" exact="boceprevir" post="for 22 weeks or 44 weeks to standard therapy"/>
  <result pre="HCV Serine Protease Inhibitor Boceprevir and PegIntron/Rebetol 2) trial evaluated" exact="boceprevir" post="for the treatment of patients who had experienced a"/>
  <result pre="rates were significantly higher for patients who received peginterferon-ribavirin plus" exact="boceprevir" post="treatment for 32 weeks (59%) or 44 weeks (66%)"/>
  <result pre="logistic regression analysis, the baseline factors associated with SVR were" exact="boceprevir" post="use, previous relapse (compared with previous nonresponder), low viral"/>
  <result pre="with peginterferon and ribavirin. The most common adverse effects of" exact="boceprevir" post="are flulike illness, fatigue, nausea, dysgeusia, and anemia.194 The"/>
  <result pre="flulike illness, fatigue, nausea, dysgeusia, and anemia.194 The addition of" exact="boceprevir" post="nearly doubled the rate of anemia compared with the"/>
  <result pre="of anemia compared with the use of standard peginterferon and" exact="ribavirin" post="therapy, with many patients requiring the use of erythropoietin.195"/>
  <result pre="binding reversibly to nonstructural 3 serine protease. After oral administration," exact="telaprevir" post="achieves peak plasma concentrations in 4 to 5 hours."/>
  <result pre="3 international randomized double-blind placebo-controlled clinical trial, the addition of" exact="telaprevir" post="to the standard treatment of peginterferon-ribavirin was associated with"/>
  <result pre="Specifically, the group of patients who received 12 weeks of" exact="telaprevir" post="combined with peginterferon-ribavirin, followed by peginterferon-ribavirin for 12 weeks"/>
  <result pre="standard therapy among patients who received only 8 weeks of" exact="telaprevir" post="combined with peginterferon-ribavirin (69% vs 44%).201 In the second"/>
  <result pre="44%).201 In the second randomized phase 3 trial that evaluated" exact="telaprevir" post="in treatment-experienced patients with HCV genotype 1 infection, the"/>
  <result pre="treatment-experienced patients with HCV genotype 1 infection, the addition of" exact="telaprevir" post="to the standard treatment regimen of peginterferon-α and ribavirin"/>
  <result pre="of telaprevir to the standard treatment regimen of peginterferon-α and" exact="ribavirin" post="was associated with significantly higher SVR rates compared with"/>
  <result pre="peginterferon-ribavirin alone.202 Collectively, these studies indicate that the addition of" exact="telaprevir" post="to standard peginterferon-ribavirin therapy can significantly improve SVR rates"/>
  <result pre="ribavirin. As a result of these findings, the FDA approved" exact="telaprevir" post="(750 mg 3 times daily) for this treatment indication."/>
  <result pre="most infections, such as acyclovir for herpes simplex virus and" exact="ganciclovir" post="for CMV. However, other of these &quot;old�? antiviral drugs"/>
  <result pre="for CMV. However, other of these &quot;old�? antiviral drugs (eg," exact="amantadine" post="and rimantadine for influenza virus infections) have lost their"/>
  <result pre="However, other of these &quot;old�? antiviral drugs (eg, amantadine and" exact="rimantadine" post="for influenza virus infections) have lost their clinical utility"/>
  <result pre="1985;151:362-3653881542 16.PerazellaMACrystal-induced acute renal failure. Am J Med. 1999;106:459-46510225250 17.HelldénALyckeJVanderTSvenssonJOOdar-CederlofIStahleLThe" exact="aciclovir" post="metabolite CMMG is detectable in the CSF of subjects"/>
  <result pre="detectable in the CSF of subjects with neuropsychiatric symptoms during" exact="aciclovir" post="and valaciclovir treatment. J Antimicrob Chemother. 2006;57:945-94916540518 18.ErnstMEFraneyRJAcyclovir- and"/>
  <result pre="the CSF of subjects with neuropsychiatric symptoms during aciclovir and" exact="valaciclovir" post="treatment. J Antimicrob Chemother. 2006;57:945-94916540518 18.ErnstMEFraneyRJAcyclovir- and ganciclovir-induced neurotoxicity."/>
  <result pre="Clin Microbiol. 2004;42:242-24914715760 23.BaconTHLevinMJLearyJJSariskyRTSuttonDHerpes simplex virus resistance to acyclovir and" exact="penciclovir" post="after two decades of antiviral therapy. Clin Microbiol Rev."/>
  <result pre="of poxvirus infections. Viruses. 2010;2:2740-276221499452 29.WolfDLRodriguezCAMucciMIngrossoADuncanBANickensDJPharmacokinetics and renal effects of" exact="cidofovir" post="with a reduced dose of probenecid in HIV-infected patients"/>
  <result pre="and renal effects of cidofovir with a reduced dose of" exact="probenecid" post="in HIV-infected patients with cytomegalovirus retinitis. J Clin Pharmacol."/>
  <result pre="Clin Pharmacol. 2003;43:43-5112520627 30.CundyKCClinical pharmacokinetics of the antiviral nucleotide analogues" exact="cidofovir" post="and adefovir. Clin Pharmacokinet. 1999;36:127-14310092959 31.KendleJBFan-HavardPCidofovir in the treatment"/>
  <result pre="of isolates from cytomegalovirus retinitis patients receiving first- or second-line" exact="cidofovir" post="therapy: relationship to clinical outcome. J Infect Dis. 1998;178:1821-18259815243"/>
  <result pre="Retinitis and Viral Resistance Study GroupIncidence of foscarnet resistance and" exact="cidofovir" post="resistance in patients treated for cytomegalovirus retinitis. Antimicrob Agents"/>
  <result pre="for cytomegalovirus retinitis. Antimicrob Agents Chemother. 1998;42:2240-22449736542 34.SnoeckRDe ClercqERole of" exact="cidofovir" post="in the treatment of DNA virus infections, other than"/>
  <result pre="Opin Investig Drugs. 2002;3:1561-1566 35.ChaSJohnstonLNatkunamYBrownJTreatment of verruca vulgaris with topical" exact="cidofovir" post="in an immunocompromised patient: a case report and review"/>
  <result pre="and review of the literature. Transpl Infect Dis. 2005;7:158-16116390407 36.LamothFPascualMErardVVenetzJPNseirGMeylanPLow-dose" exact="cidofovir" post="for the treatment of polyomavirus-associated nephropathy: two case reports"/>
  <result pre="reports and review of the literature. Antivir Ther. 2008;13:1001-100919195325 37.ToroJRSanchezSTurianskyGBlauveltATopical" exact="cidofovir" post="for the treatment of dermatologic conditions: verruca, condyloma, intraepithelial"/>
  <result pre="1994;170:570-5728077713 39.BryantPSasadeuszJCarapetisJWatersKCurtisNSuccessful treatment of foscarnet-resistant herpes simplex stomatitis with intravenous" exact="cidofovir" post="in a child. Pediatr Infect Dis J. 2001;20:1083-108611734717 40.KoppTGeusauARiegerAStinglGSuccessful"/>
  <result pre="treatment of an aciclovir-resistant herpes simplex type 2 infection with" exact="cidofovir" post="in an AIDS patient. Br J Dermatol. 2002;147:134-13812100196 41.GarveyLThomsonECTaylorGPProgressive"/>
  <result pre="a case series. AIDS. 2006;20:791-79316514320 42.MarraCMRajicicNBarkerDEet al.A pilot study of" exact="cidofovir" post="for progressive multifocal leukoencephalopathy in AIDS. AIDS. 2002;16:1791-179712218391 43.RazonableRRAksamitAJWrightAJWilsonJWCidofovir"/>
  <result pre="highly active antiretroviral therapy. Mayo Clin Proc. 2001;76:1171-117511702907 44.Segarra-NewnhamMVodoloKMUse of" exact="cidofovir" post="in progressive multifocal leukoencephalopathy. Ann Pharmacother. 2001;35:741-74411408993 45.ViallardJFLazaroEEllieEet al.Improvement"/>
  <result pre="Ann Pharmacother. 2001;35:741-74411408993 45.ViallardJFLazaroEEllieEet al.Improvement of progressive multifocal leukoencephalopathy after" exact="cidofovir" post="therapy in a patient with a destructive polyarthritis. Infection."/>
  <result pre="cidofovir. J Antimicrob Chemother. 2007;60:193-19417496056 49.AmbatiJWynneKBAngerameMCRobinsonMRAnterior uveitis associated with intravenous" exact="cidofovir" post="use in patients with cytomegalovirus retinitis. Br J Ophthalmol."/>
  <result pre="clinical pharmacokinetics of famciclovir. Clin Pharmacokinet. 1996;31:1-88827396 52.FaroSA review of" exact="famciclovir" post="in the management of genital herpes. Infect Dis Obstet"/>
  <result pre="review of new single-day dosing indications. Cutis. 2007;80:77-8117725069 54.SaltzmanRJurewiczRBoonRSafety of" exact="famciclovir" post="in patients with herpes zoster and genital herpes. Antimicrob"/>
  <result pre="Group; Cytomegalovirus Cooperative Study GroupA randomized, controlled study of intravenous" exact="ganciclovir" post="therapy for cytomegalovirus peripheral retinitis in patients with AIDS."/>
  <result pre="1993;168:557-5638394858 69.DrewWLIvesDLalezariJPet al.; collab: Syntex Cooperative Oral Ganciclovir Study GroupOral" exact="ganciclovir" post="as maintenance treatment for cytomegalovirus retinitis in patients with"/>
  <result pre="Transplantation Study GroupRandomised trial of efficacy and safety of oral" exact="ganciclovir" post="in the prevention of cytomegalovirus disease in liver-transplant recipients"/>
  <result pre="Lancet. 1997;350:1729-17339413463 71.EidAJArthursSKDezielPJWilhelmMPRazonableRREmergence of drug-resistant cytomegalovirus in the era of" exact="valganciclovir" post="prophylaxis: therapeutic implications and outcomes. Clin Transplant. 2008;22:162-17018339135 72.SariskyRTBaconTHBoonRJet"/>
  <result pre="prophylaxis: therapeutic implications and outcomes. Clin Transplant. 2008;22:162-17018339135 72.SariskyRTBaconTHBoonRJet al.Profiling" exact="penciclovir" post="susceptibility and prevalence of resistance of herpes simplex virus"/>
  <result pre="isolates across eleven clinical trials. Arch Virol. 2003;148:1757-176914505088 73.BaconTHBoydMRActivity of" exact="penciclovir" post="against Epstein-Barr virus. Antimicrob Agents Chemother. 1995;39:1599-16027492112 74.SpruanceSLReaTLThomingCTuckerRSaltzmanRBoonR; collab:"/>
  <result pre="Valaciclovir HSV Study GroupA large-scale, placebo-controlled, dose-ranging trial of peroral" exact="valaciclovir" post="for episodic treatment of recurrent herpes genitalis. Arch Intern"/>
  <result pre="immunocompromised hosts. Expert Rev Anti Infect Ther. 2004;2:27-4115482169 80.BrownFBankenLSaywellKArumIPharmacokinetics of" exact="valganciclovir" post="and ganciclovir following multiple oral dosages of valganciclovir in"/>
  <result pre="Expert Rev Anti Infect Ther. 2004;2:27-4115482169 80.BrownFBankenLSaywellKArumIPharmacokinetics of valganciclovir and" exact="ganciclovir" post="following multiple oral dosages of valganciclovir in HIV- and"/>
  <result pre="80.BrownFBankenLSaywellKArumIPharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of" exact="valganciclovir" post="in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet. 1999;37:167-17610496303 81.WiltshireHHirankarnSFarrellCet"/>
  <result pre="and CMV-seropositive volunteers. Clin Pharmacokinet. 1999;37:167-17610496303 81.WiltshireHHirankarnSFarrellCet al.Pharmacokinetic profile of" exact="ganciclovir" post="after its oral administration and from its prodrug, valganciclovir,"/>
  <result pre="organ transplant recipients. Clin Pharmacokinet. 2005;44:495-50715871635 82.CaldesAColomHArmendarizYet al.Population pharmacokinetics of" exact="ganciclovir" post="after intravenous ganciclovir and oral valganciclovir administration in solid"/>
  <result pre="Clin Pharmacokinet. 2005;44:495-50715871635 82.CaldesAColomHArmendarizYet al.Population pharmacokinetics of ganciclovir after intravenous" exact="ganciclovir" post="and oral valganciclovir administration in solid organ transplant patients"/>
  <result pre="82.CaldesAColomHArmendarizYet al.Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral" exact="valganciclovir" post="administration in solid organ transplant patients infected with cytomegalovirus."/>
  <result pre="cytomegalovirus. Antimicrob Agents Chemother. 2009;53:4816-482419738014 83.MartinDFSierra-MaderoJWalmsleySet al.A controlled trial of" exact="valganciclovir" post="as induction therapy for cytomegalovirus retinitis. N Engl J"/>
  <result pre="N Engl J Med. 2002;346:1119-112611948271 84.PayaCHumarADominguezEet al.Efficacy and safety of" exact="valganciclovir" post="vs. oral ganciclovir for prevention of cytomegalovirus disease in"/>
  <result pre="Med. 2002;346:1119-112611948271 84.PayaCHumarADominguezEet al.Efficacy and safety of valganciclovir vs. oral" exact="ganciclovir" post="for prevention of cytomegalovirus disease in solid organ transplant"/>
  <result pre="recipients. Am J Transplant. 2004;4:611-62015023154 85.KhouryJAStorchGABohlDLet al.Prophylactic versus preemptive oral" exact="valganciclovir" post="for the management of cytomegalovirus infection in adult renal"/>
  <result pre="adult renal transplant recipients. Am J Transplant. 2006;6:2134-214316780548 86.SnydmanDRUse of" exact="valganciclovir" post="for prevention and treatment of cytomegalovirus disease [editorial]. Clin"/>
  <result pre="of cytomegalovirus disease [editorial]. Clin Infect Dis. 2008;46:28-2918171209 87.EinseleHReusserPBornhauserMet al.Oral" exact="valganciclovir" post="leads to higher exposure to ganciclovir than intravenous ganciclovir"/>
  <result pre="Dis. 2008;46:28-2918171209 87.EinseleHReusserPBornhauserMet al.Oral valganciclovir leads to higher exposure to" exact="ganciclovir" post="than intravenous ganciclovir in patients following allogeneic stem cell"/>
  <result pre="al.Oral valganciclovir leads to higher exposure to ganciclovir than intravenous" exact="ganciclovir" post="in patients following allogeneic stem cell transplantation. Blood. 2006;107:3002-300816352807"/>
  <result pre="solid organ transplant recipients. Clin Infect Dis. 2008;46:20-2718171208 89.AsbergAHumarARollagHet al.Oral" exact="valganciclovir" post="is noninferior to intravenous ganciclovir for the treatment of"/>
  <result pre="Infect Dis. 2008;46:20-2718171208 89.AsbergAHumarARollagHet al.Oral valganciclovir is noninferior to intravenous" exact="ganciclovir" post="for the treatment of cytomegalovirus disease in solid organ"/>
  <result pre="in current clinical use. J Clin Virol. 2004;30:115-13315125867 92.TappendenPJacksonRCooperKet al.Amantadine," exact="oseltamivir" post="and zanamivir for the prophylaxis of influenza (including a"/>
  <result pre="clinical use. J Clin Virol. 2004;30:115-13315125867 92.TappendenPJacksonRCooperKet al.Amantadine, oseltamivir and" exact="zanamivir" post="for the prophylaxis of influenza (including a review of"/>
  <result pre="and economic evaluation. Health Technol Assess. 2009;13(11):iii,ix-xii, 1-246 93.BettsRFAmantadine and" exact="rimantadine" post="for the prevention of influenza A. Semin Respir Infect."/>
  <result pre="influenza A. Semin Respir Infect. 1989;4:304-3102697053 94.KrumbholzASchmidtkeMBergmannSet al.High prevalence of" exact="amantadine" post="resistance among circulating European porcine influenza A viruses. J"/>
  <result pre="2009;44:91-9319019729 96.HaydenFGHayAJEmergence and transmission of influenza A viruses resistant to" exact="amantadine" post="and rimantadine. Curr Top Microbiol Immunol. 1992;176:119-1301600749 97.HaydenFGSperberSJBelsheRBCloverRDHayAJPykeSRecovery of"/>
  <result pre="Chemother. 2005;55(suppl 1):i5-i2115709056 99.SugayaNTamuraDYamazakiMet al.Comparison of the clinical effectiveness of" exact="oseltamivir" post="and zanamivir against influenza virus infection in children. Clin"/>
  <result pre="1):i5-i2115709056 99.SugayaNTamuraDYamazakiMet al.Comparison of the clinical effectiveness of oseltamivir and" exact="zanamivir" post="against influenza virus infection in children. Clin Infect Dis."/>
  <result pre="a review of clinical safety. Drug Saf. 1999;21:267-28110514019 107.GaurAHBaggaBBarmanSet al.Intravenous" exact="zanamivir" post="for oseltamivir-resistant 2009 H1N1 influenza [letter]. N Engl J"/>
  <result pre="B. N Engl J Med. 2005;352:2682-269515987917 117.MarcellinPLauGKBoninoFet al.Peginterferon alfa-2a alone," exact="lamivudine" post="alone, and the two in combination in patients with"/>
  <result pre="118.JanssenHLvan ZonneveldMSenturkHet al.Pegylated Interferon alfa-2b alone or in combination with" exact="lamivudine" post="for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet."/>
  <result pre="C. Cochrane Database Syst Rev. 2010;(1):CD00544520091577 128.FriedMWShiffmanMLReddyKRet al.Peginterferon alfa-2a plus" exact="ribavirin" post="for chronic hepatitis C virus infection. N Engl J"/>
  <result pre="infection. N Engl J Med. 2002;347:975-98212324553 129.MannsMPMcHutchisonJGGordonSCet al.Peginterferon alfa-2b plus" exact="ribavirin" post="compared with interferon alfa-2b plus ribavirin for initial treatment"/>
  <result pre="129.MannsMPMcHutchisonJGGordonSCet al.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus" exact="ribavirin" post="for initial treatment of chronic hepatitis C: a randomised"/>
  <result pre="a randomized controlled trial. JAMA. 2004;292:2839-284815598915 132.TorrianiFJRodriguez-TorresMRockstrohJKet al.Peginterferon Alfa-2a plus" exact="ribavirin" post="for chronic hepatitis C virus infection in HIV-infected patients."/>
  <result pre="patients. N Engl J Med. 2004;351:438-45015282351 133.ChungRTAndersenJVolberdingPet al.Peginterferon Alfa-2a plus" exact="ribavirin" post="versus interferon alfa-2a plus ribavirin for chronic hepatitis C"/>
  <result pre="2004;351:438-45015282351 133.ChungRTAndersenJVolberdingPet al.Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus" exact="ribavirin" post="for chronic hepatitis C in HIV-coinfected persons. N Engl"/>
  <result pre="147.AgestaNZabalaRDiaz-PerezJLAlopecia areata during interferon alpha-2b/ribavirin therapy. Dermatology. 2002;205:300-30112399683 148.WadeJRSnoeckEDuffFLambMJorgaKPharmacokinetics of" exact="ribavirin" post="in patients with hepatitis C virus. Br J Clin"/>
  <result pre="intravenously administered ribavirin. Antimicrob Agents Chemother. 1990;34:489-4902334164 150.GishRGTreating HCV with" exact="ribavirin" post="analogues and ribavirin-like molecules. J Antimicrob Chemother. 2006;57:8-1316293677 151.GluudLLMarchesiniEIorioAPeginterferon"/>
  <result pre="analogues and ribavirin-like molecules. J Antimicrob Chemother. 2006;57:8-1316293677 151.GluudLLMarchesiniEIorioAPeginterferon plus" exact="ribavirin" post="for chronic hepatitis C in patients with human immunodeficiency"/>
  <result pre="children. Cochrane Database Syst Rev. 2007;CD00018117253446 153.PelaezALyonGMForceSDet al.Efficacy of oral" exact="ribavirin" post="in lung transplant patients with respiratory syncytial virus lower"/>
  <result pre="Transplant. 2009;28:67-7119134533 154.KnowlesSRPhillipsEJDresserLMatukasLCommon adverse events associated with the use of" exact="ribavirin" post="for severe acute respiratory syndrome in Canada. Clin Infect"/>
  <result pre="los ReyesECet al.Treatment of severe La Crosse encephalitis with intravenous" exact="ribavirin" post="following diagnosis by brain biopsy. Pediatrics. 1997;99:261-2679024460 157.ChongHTKamarulzamanATanCTet al.Treatment"/>
  <result pre="1986;314:20-263940312 159.HugginsJWHsiangCMCosgriffTMet al.Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous" exact="ribavirin" post="therapy of hemorrhagic fever with renal syndrome. J Infect"/>
  <result pre="treated with oral ribavirin. Lancet. 1995;346:472-4757637481 161.MardaniMJahromiMKNaieniKHZeinaliMThe efficacy of oral" exact="ribavirin" post="in the treatment of Crimean-Congo hemorrhagic fever in Iran."/>
  <result pre="J Antimicrob Chemother. 2007;59:827-83217332007 170.LimSGNgTMKungNet al.A double-blind placebo-controlled study of" exact="emtricitabine" post="in chronic hepatitis B. Arch Intern Med. 2006;166:49-5616401810 171.SimsKAWoodlandAMEntecavir:"/>
  <result pre="pharmacokinetics of lamivudine. Clin Pharmacokinet. 1999;36:41-669989342 175.DienstagJLPerrilloRPSchiffERBartholomewMVicaryCRubinMA preliminary trial of" exact="lamivudine" post="for chronic hepatitis B infection. N Engl J Med."/>
  <result pre="al.; collab: Asia Hepatitis Lamivudine Study GroupA one-year trial of" exact="lamivudine" post="for chronic hepatitis B. N Engl J Med. 1998;339:61-689654535"/>
  <result pre="ManRAHeijtinkRASchalmSWHepatitis B reactivation after lamivudine. Lancet. 1995;346:1156-11577475613 179.ZhouXJKeJSallasWMFarrellCMayersDLPentikisHSPopulation pharmacokinetics of" exact="telbivudine" post="and determination of dose adjustment for patients with renal"/>
  <result pre="on telbivudine. Int J Clin Pract. 2006;60:1295-129916981973 182.LaiCLGaneELiawYFet al.Telbivudine versus" exact="lamivudine" post="in patients with chronic hepatitis B. N Engl J"/>
  <result pre="al.Treatment of hepatitis B e antigen positive chronic hepatitis with" exact="telbivudine" post="or adefovir: a randomized trial. Ann Intern Med. 2007;147:745-75417909201"/>
  <result pre="fumarate: role in hepatitis B treatment. Hepatology. 2006;44:309-31316871562 188.ReijndersJGJanssenHLPotency of" exact="tenofovir" post="in chronic hepatitis B: mono or combination therapy?J Hepatol."/>
  <result pre="STDS. 2008;22:99-10318260800 191.SchmidSOpravilMModdelMet al.Acute interstitial nephritis of HIV-positive patients under" exact="atazanavir" post="and tenofovir therapy in a retrospective analysis of kidney"/>
  <result pre="191.SchmidSOpravilMModdelMet al.Acute interstitial nephritis of HIV-positive patients under atazanavir and" exact="tenofovir" post="therapy in a retrospective analysis of kidney biopsies. Virchows"/>
  <result pre="protease inhibitor telaprevir. Gastroenterology. 2007;132:1767-177717484874 199.McHutchisonJGEversonGTGordonSCet al.Telaprevir with peginterferon and" exact="ribavirin" post="for chronic HCV genotype 1 infection. N Engl J"/>
  <result pre="J Med. 2009;360:1827-183819403902 200.HézodeCForestierNDusheikoGet al.Telaprevir and peginterferon with or without" exact="ribavirin" post="for chronic HCV infection. N Engl J Med. 2009;360:1839-185019403903"/>
 </snippets>
</snippetsTree>
